AEON Biopharma appoints John Bencich as CFO, amends inducement plan by 1M shares

AEON Biopharma, Inc.

John Bencich appointed CFO effective March 9, 2026; base salary $450k, bonus target 40%.
Equity grants: 754,717 RSUs (4-year vest) and 235,849 PSUs tied to NYSE American compliance.
Jennifer Sy enters CAO employment agreement with $275k base, 30% bonus target, and severance terms.
Board adds 1,000,000 shares to 2025 Inducement Plan for equity awards without stockholder approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.